Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H20Br2N2 |
Molecular Weight | 376.13 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CC1=C(N)C(Br)=CC(Br)=C1)C2CCCCC2
InChI
InChIKey=OJGDCBLYJGHCIH-UHFFFAOYSA-N
InChI=1S/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3
Molecular Formula | C14H20Br2N2 |
Molecular Weight | 376.13 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:20:48 UTC 2023
by
admin
on
Fri Dec 15 15:20:48 UTC 2023
|
Record UNII |
Q1J152VB1P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
R05CB02
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
||
|
LIVERTOX |
122
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
||
|
WHO-VATC |
QR05CB02
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
||
|
FDA ORPHAN DRUG |
34789
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL253376
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
DB09019
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
Q1J152VB1P
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
100000088676
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
C172826
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
m2668
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | Merck Index | ||
|
402
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
3572-43-8
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
222-684-1
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
77032
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
DTXSID6022686
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
D001964
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
BROMHEXINE
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
SUB05914MIG
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
2442
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
1753
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | RxNorm | ||
|
Q1J152VB1P
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY | |||
|
2584
Created by
admin on Fri Dec 15 15:20:48 UTC 2023 , Edited by admin on Fri Dec 15 15:20:48 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Activation of TMPRSS2 plays an important role in viral respiratory diseases such as influenza A and Middle East Respiratory Syndrome (MERS). Inhibition of receptor activation and viral entry by bromhexine may be effective in preventing or treating various respiratory illnesses, including COVID-19.5 In vitro studies have suggested the action of ambroxol (a metabolite of bromhexine) on the angiogensin-converting enzyme receptor 2 (ACE2), prevents entry of the viral envelope-anchored spike glycoprotein of SARS-Cov-2 into alveolar cells or increases the secretion of surfactant, preventing viral entry.
IC50
|
||
|
BINDER->LIGAND |
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
When bromhexine is administered orally, the systemic exposure to ambroxol is much lower (;8-fold; Liu et al., 2010), but since the true molecular action of these agents is not entirely known, it cannot be ascertained whether bromhexine or ambroxol, or both, contribute to activity. Ambroxol has also been associated with a reduction in throat pain, which has triggered investigation into the activity of it and bromhexine at sodium channels (such as NaV1.8 and the tetrodotoxin sensitive channel; Leffler et al., 2010).
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
MINOR
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |